Researchers reported that NUP62 silencing can reverse resistance to osimertinib in non-small cell lung cancer models, aiming at a core mechanism behind failure of third-generation EGFR-TKIs. The work frames osimertinib as frontline treatment for EGFR-activating NSCLC, while resistance remains a major barrier to durable control. The provided account characterizes the strategy as a potential way to re-sensitize resistant tumors, shifting the focus toward restoring drug responsiveness rather than switching entirely to next-line agents. The findings add to the expanding map of resistance biology for EGFR-TKIs and could support future preclinical and translational efforts targeting NUP62-linked pathways.